Inovio Pharmaceuticals Inc vs OneSpan Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while OneSpan Inc trades at $16.57 (market cap $600.69M). The key difference: OneSpan Inc is far larger — about 7.6× Inovio Pharmaceuticals Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | OSPN | |
|---|---|---|
Market Cap | $78.55M | $600.69M |
Sector | Health | Technology |
52-Week High | $2.87 | $16.78 |
52-Week Low | $0.66 | $10.15 |
Enterprise Value | $49.56M | $569.77M |
Dividend Yield | — | 3.19% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
OneSpan (OSPN) trades at $16.17, down 1.22% today, with strong fundamental metrics including a P/E of 9.21 and net income margin of 27.76%. The stock shows bullish technical signals with recent earnings beats and analyst consensus pointing to upside potential. Recent product launches like DigipassONE demonstrate ongoing innovation in authentication solutions.
The outlook remains positive with 67% analyst buy ratings and a $17.00 consensus target. Risks include declining operating cash flow and competitive pressure in the software security space. The stock offers value characteristics with reasonable valuation multiples and consistent dividend payments.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →